Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.25 3.76% 6.90 1,199,811 14:19:49
Bid Price Offer Price High Price Low Price Open Price
6.70 7.10 6.95 6.60 6.65
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Nonequity Investment Instruments 0.61 -1.84 -0.36 32
Last Trade Time Trade Type Trade Size Trade Price Currency
16:27:35 O 50,000 7.10 GBX

Nuformix (NFX) Latest News

More Nuformix News
Nuformix Takeover Rumours

Nuformix (NFX) Share Charts

1 Year Nuformix Chart

1 Year Nuformix Chart

1 Month Nuformix Chart

1 Month Nuformix Chart

Intraday Nuformix Chart

Intraday Nuformix Chart

Nuformix (NFX) Discussions and Chat

Nuformix Forums and Chat

Date Time Title Posts
16/10/201921:02Nuformix plc2,822

Add a New Thread

Nuformix (NFX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-16 15:27:357.1050,0003,550.00O
2019-10-16 15:16:577.08140,4149,941.31O
2019-10-16 15:09:037.0830,0002,124.00O
2019-10-16 14:33:017.0250,0003,510.00O
2019-10-16 14:29:556.847,426507.57O
View all Nuformix trades in real-time

Nuformix (NFX) Top Chat Posts

Nuformix Daily Update: Nuformix Plc is listed in the Nonequity Investment Instruments sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 6.65p.
Nuformix Plc has a 4 week average price of 5.70p and a 12 week average price of 5.70p.
The 1 year high share price is 14.75p while the 1 year low share price is currently 1.60p.
There are currently 460,750,000 shares in issue and the average daily traded volume is 1,115,996 shares. The market capitalisation of Nuformix Plc is £31,791,750.
pennyfalls: Morning Soup, Indie and all... Some good points there Soup.. This is how I see things panning out in your Doomsday scenario: Chinese walk away, so we don't get the cash. The Patent is either stolen/not stolen. Whichever way, this obviously wacks the share price. So, NFX at this point is down to , say 3p, 4p. It needs funds so has to have maybe £2Million fundraiser at circa 2- 3p I would suggest. This is self-limiting in damage apart from the 10-20% dilution. Personally, I do not believe Dan's team have the personnel capability or drive to go out seeking ROW rights for Nfx001, reading between the lines. They want the tech, and may use it for other offshoots.. So, I agree that the Doomsday scenario is limited to a short-medium term shareprice hit, before it picks up again going into other trials. Who knows, maybe not having the Chinese involved will allow NFX to get a decent Broker and be a long-term positive.
pennyfalls: Darlings! I've been thinking about this Chinese money situation... To me there are 5 possible outcomes: 1) Chinese money comes through in a (somewhat) timely fashion and everyone happy. Shareprice hits 10p-ish and maintains or higher. 2) Same situation but shareprice spikes up to 10p - many sell on spike, falls back to 6/7p until next nfx002 licensing news late 2019. Then off it goes again. 3)Dan keeps procrastinating on the "forever" news in 2 weeks situation - eventually leading to a Brexit style uncertainty, sliding share price and ultimately fundraiser circa 3p. Chinese situation goes on and on. 4) Chinese pull out unilaterally (which they can contractually if anyone read it) and nick patent, shareprice drops to 3p. Fundraise at 2p. 5) Chinese are bargaining for more of Nxp001 and nxpoo2 and maybe more - they strike a compromise deal which soothes markets, but isn't great for Nfx long-term. All speculative...views appreciated :o)
soupdragon55: Ok, Jak. 1. Correct at 6p mcap is £28m. 2. Balance sheet at finals was from March 31st. Remind me what todays date is? 3. Again, you're talking year end, so nearly 6 months ago. Cash is not 4k now as you note in you're point no. 4. 4. Since yr end, received 500k Ebers up front plus a milestone payment for patent filing last week. Then there is the pending £2.5m. Therefore as you are expecting NSB to honour their contract. How do you view the year end 2020 balance sheet? 5. Cash burn is circa 900k p.a. (you obviously read and accepted my previous post addressed to you the other week about exceptionals) 6. Debt to equity conversion rate of 2.75p was set in August 2018 when the prevailing share price was 2.5p. 7. Correct, the majority of warrants are in the 4-10p range.
jaknife: Pennyfalls, I don't think that ANY sensible investor cares about a "gap" being filled in a candlestick. What they really care about is fundamentals! 1. At a 6p share price the market cap is £28m 2. This compares to a tangible balance sheet at the finals of minus £450k (ie a technically insolvent balance sheet): Https:// 3. Cash as at year-end was £4,261 (no missing "k" or "m", this really is the same sort of cash that you'd find in a pub at closing time). 4. Since year-end they've received a milestone payment of £500k Https:// 5. But cash burn is high and broker forecast are for a loss this year 6. They've also had to do a debt for equity conversion on a loan because they don't have adequate cash to repay the loan: Https:// Note how they issued shares at 2.75p for this, a material discount to the current share price! 7. And the notes (19) to the finals reveal that there are a material number of warrants and share options out there with strike prices typically at 4p! So in summary, this is a company with a hopelessly weak balance sheet that desperately needs cash that has issued lots of pieces of paper to its best friends that let its friends buy shares for as little as 2.75p and at most 4p. And it's got a speculative business model in blah blah blah Cannabinoids, which just so happens to be this week's latest buzzword. And it's being ramped across social media and bulletin boards at a time when the share price is falling sharply! What a complete and obvious dog! JakNife
pennyfalls: Regarding China, that was my initial misgiving with investing in nfx, having personally seen companies screwed by the Chinese. But when the first two payments went through without a problem, I thought maybe this is different. Obviously things have changed somehow after New summit were engulfed buy a bigger organisation. The result of which is still to be seen, and we're suffering from ATM. Ps Indie, regarding Aimys continual ramps, yes I agree, and some have been stung by that, but I guess that im saying that people have got wise to him and share price has found its true level. But I agree, that he's the worst poster I've ever seen on a message board, in that he shut down debate, tried to control the agenda, has a 1 theme mantra, and is a nasty piece of work... A theme that is unfortunately increasing on public message boards.
pennyfalls: I think Chrisrainy on L-S-E summed it all up best in one line this morning. "Switch off for 6 months" Hard to do, but I think there's some big short-term share price volatility on the horizon - as the main driver here short term is the background seller fed by Chinese uncertainty - sounds to me like they want more NFX for their buck.. Technically the 50/200 day moving average is gradually creeping back to a negative crossover (Ive been keeping an eye on this with concern and it guided my decision a little the other day to sell some.) However, In 4- 5 months, Spreadex will be gone (and maybe CPI) we'll have a Chinese resolution (either way), news of new nfx002 licensing deals, and nfx002 will be approaching trials. There'll be probably more meat on cannabinoids bones at that point...and I expect a big uplift approaching the nfx002 human trials, if things go to plan. Keep an eye on RNS alerts on and try to switch off to the share price for a bit, is maybe the best plan. Ps..also just my considered opinion - but I think this Rest of World Rights for nfx001 is BS. (my opinion based on my what I've heard- and reading between lines) . Basically, remember what this company is about - they aren't particularly bothered about sales (as Dan already revised his strategy , wanting MORE upfront cash , less Royalties - they want a big sell-off of potential, patents , drugs under belt, and proven tech. Royalties are a way of getting cash in to develop more - and get to that final goal sooner. AND - what is going on with Nfx003.. What is it, ? does it even exist any more?
pennyfalls: Meijiman - thanks for that :o) yes, I forgot about research notes! That would be useful with a thought-out forward valuation. Always good to have it laid out with an independent analysis and target price - and usually provides a boost to the share price. Regarding Broker share price ‘management217;..? Maybe one day you can explain further whe you have a spare few minutes. Anyway, much appreciated.
pennyfalls: Hey Jiving, good to see you on here - a good level-headed poster from yesteryear. Stick around. Thanks FishyBazza - think you need some chlorine for that filthy mouth of yours! Haha.. Indeedy, Aim4Utopia/ Sailorlad, has been predicting “lots of news” every week since the time of Moses - but like a broken clock , he will be correct twice a day (or year, in his case). However, his clock may just be getting round to the point where it’s correct once more, and I think it could be time for some good news. The near/medium term factor regarding share price movement IMO is how any near-term good news balances and offsets the cash-problems with the Chinese. How will the Markets balance and judge the value of NFX , with a weight hanging around its ankles. When will the Chinese pay? There’s some fair chance the Chinese situation will be resolved, I believe, but Markets hate uncertainty, and it seems Brokers hate the Chinese!...So...where are we at?? ( I wish Dan hadn’t said £500K money due in a a few days , many weeks ago, the Market like that even less). Maybe he’ll learn from that one, although I think he’s great and tries to be open and honest with investors. Top CEO. NFX progresses apace with all its other projects, and seems to be going well, but how much can/ will it rise with the Chinese funding still unanswered. Could it be, ultimately , that if they don’t cough up before a certain deadline, that NFX has to be ruthless (in a BOJO-esque cull) and terminate the deal - and be rid of them for the greater future prospects of the company? If that was the case, the shareprice would take a short-term hit, but would allow it to prosper untarnished. It’s hard to judge how the Market sees all this and balances potential with uncertainty.
pennyfalls: Hi Indie and Bazza-Fish.. I don't know if Aim4Utopia/ Sailorboy was/ is a "paid" ramper. TBH I'm not convinced, as I remember his early posts, which seemed to be excited and boastful of getting in low (which turned out to be not the lowest) Also, the Cannabinoids deal did its own Ramping (along with 'basecamp Taffy!) - and, despite an unremitting cascade of Rampy posts, it has not made a jot of difference to the share price recently with the Spreadex/other sales going through. Indeed, it’s probably found a more realistic equilibrium now until next news. I still await the Chinese Funding. Most boards (oil and Gas, Pharma) do have expert commentators among the tripe. NFX doesn't (either here or LSE)..there’s no experts (inc myself in that). It’s resulted in very depressingly 2-dimensional unhelpful rhetoric. There are no scientists on board, or posters of co-crystal experience to gauge company progress compared to other Business's out there. I found the LSE nfx message board the most depressing I've ever been on, and I've been investing for 20+years and been on message boards a good 10 of those. It leaves me with a bad taste about NFX to be honest, and a general unease, but this may be wrongly conflating bad posters with the company.
thefartingcommie: Doofu Posts: 487 Price: 10.75 Strong Buy NFX - For what it’s worth...Tue 19:02 Good Evening, I just wanted to say, please can we just take a small step back and reflect calmly as to where we are. We recently had a company validating/watershed moment with the Bioavailability approval/positive result for our lead co-crystal NPX 001 drug. The positive results from the trial now enable the Company to: · Confirm NXP001's potential for development as a treatment for CINV, enabling current and future licensees to launch new products into the £16bn oncology supportive care market · Trigger a final milestone payment of £2m from its Chinese licensing partner, Newsummit Biopharma, who have commenced product registration in China (Nuformix retains 10% royalty, with remaining milestone payments expected during June 2019) · Progress on-going discussions for licensing rest of world rights to NXP001 for CINV · Finalise further product development opportunities for the NXP001 programme to generate additional future value · Progress its wider portfolio using the Company's proven approach in identifying high-value applications for cocrystal technology So whilst it is frustrating to see the share price, correct, take a breather, consolidate within what has been a new range of 10.5p - 14p now is the time for cool heads, calm reflection whilst we await the next piece of the Jigsaw to arrive. Dan and the team have skin in the game, this is main market and I for one believe that if I continue to hold and remain patient the oncology industry and NFX shareholders will be rewarded. Have a lovely evening. Doofs couldnt have put it better myself.... take a step back ..or two...go and chop some wood,play golf..etc
Nuformix share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191017 01:36:29